Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: A single or two distinct clinical entities?

Clinical Microbiology and Infection

Volumn 19, Issue 7, 2013, Pages 640-645

  Lee, Y T ^a,b   Kuo, S C ^a,c   Yang, S P ^a,d   Lin, Y T ^a,d   Chiang, D H ^a,d   Tseng, F C ^c   Chen, T L ^a,d   Fung, C P ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Chutung Veterans Hospital   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Acinetobacter baumannii; Acinetobacter nosocomialis; Antimicrobial therapy; Mortality; Pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; CYTOTOXIC AGENT; GENTAMICIN; IMIPENEM; PREDNISOLONE; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ACINETOBACTER NOSOCOMIALIS; ACINETOBACTER NOSOCOMIALIS INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD ANALYSIS; CHARLSON COMORBIDITY INDEX; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RISK FACTOR; SHOCK;

ACINETOBACTER; ACINETOBACTER BAUMANNII;

EID: 84878928129     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03988.x     Document Type: Article

References (27)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
2. Espinal P, Seifert H, Dijkshoorn L, Vila J, Roca I. Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin Microbiol Infect 2011; Oct 13; [Epub ahead of print]. doi: 10.1111/j.1469-0691.2011.03696.x.
3. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11: 868-873.
4. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 2007; 13: 117-119.
5. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R48.
6. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006; 43: 389.
7. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692-699.
8. Joung MK, Kwon KT, Kang CI et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 2010; 61: 212-218.
9. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31: 649-655.
10. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31: 2478-2482.
11. Chuang YC, Sheng WH, Li SY et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52: 352-360.
12. Lee NY, Chang TC, Wu CJ et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 2010; 61: 219-227.
13. Wisplinghoff H, Paulus T, Lugenheim M et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012; 64: 282-290.
14. Wisplinghoff H, Hippler C, Bartual SG et al. Molecular epidemiology of clinical Acinetobacter baumannii and Acinetobacter genomic species 13TU isolates using a multilocus sequencing typing scheme. Clin Microbiol Infect 2008; 14: 708-715.
15. Lee YT, Huang LY, Chiang DH et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009; 34: 580-584.
16. Lee YC, Huang YT, Tan CK et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011; 66: 1839-1846.
17. Magret M, Lisboa T, Martin-Loeches I et al. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care 2011; 15: R62.
18. Chen TL, Siu LK, Wu RC et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 2007; 13: 801-806.
19. Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT, Chang TC. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol 2005; 43: 1632-1639.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
22. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
23. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129: 102-109.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
25. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120: 1072-1077.
26. Liang-Yu C, Kuo SC, Liu CY et al. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007. J Microbiol Immunol Infect 2011; 44: 358-363.
27. Lee YT, Kuo SC, Yang SP et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012; 55: 209-215.